FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313475839> ?p ?o ?g. }

• W4313475839 abstract "Necrotic enteritis (NE) is an infectious intestinal disease caused by Clostridium perfringens (C. perfringens) that is now re-emerging and causing concern within the poultry industry. Previously, the supplementation of antibiotics in feed was the most popular control strategy against C. perfringens. However, with the ban on supplementing growth-promoting antibiotics in livestock feed, alternatives to antibiotics will be essential in order to control necrotic enteritis. A possible alternative to antibiotics could be the medium or long chain fatty acids (MCFA or LCFA) as these are able to destroy cell membranes which in turn results in the death of bacteria. In this study, the in vitro antimicrobial activity of different combinations with microencapsulated caprylic acid (C8: 0), capric acid (C10: 0), lauric acid (C12: 0) and myristic acid (C14: 0) against C. perfringens and in vivo control the NE-inducing C. perfringens in broiler chicken were analyzed.The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) assay results revealed that three different combinations of medium/long chain fatty acids varied in antimicrobial activities against C. perfringens type A strain (CVCC52, quality control), C. perfringens type A strain (C8-1), C. perfringens type G strain (D25) and C. perfringens type G strain (MZ1). Specifically, combination of C12: 0 and C14: 0 (C12-14) showed the highest antimicrobial activity against the four strains of C. perfringens (MIC ≤ 12.5 μg/mL, MBC = 50 μg/mL), followed by the combination of C10: 0 and C12: 0 (C10-12) (MIC, MBC ≤ 50 μg/mL). The in vivo study, 189 of 818-crossbred chickens that were fed a wheat-based diet and randomly divided into nine groups, with six treatment groups supplemented with either a high dose (1 g/kg) or low dose (0.5 g/kg) of three combinations respectively. The remaining three groups comsisted of a positive group supplement with avilamycin (0.01 g/kg), an infected control and an uninfected control. All chickens were challenged with C. perfringens from day 14 to day 17, except those in the uninfected control group. On day 20, the duodenum and jejunum necrotic lesions scores were calculated and the results showed that there was significant decrease in the C12-C14 high dose group (1.43 ± 0.23, 0.48 ± 0.13) and the C10-12 high dose group (1.52 ± 0.19, 0.48 ± 0.11) compared to the infected group (2.86 ± 0.21, 1.20 ± 0.28).This finding indicated that dietary microencapsulated C12-C14 and C10-C12 could inhibit the growth of C. perfringens in chickens, which proves is viability to serve as an alternative to antibiotics used for necrotic enteritis caused by C. perfringens." @default.
• W4313475839 created "2023-01-06" @default.
• W4313475839 creator A5002093049 @default.
• W4313475839 creator A5003014253 @default.
• W4313475839 creator A5012855703 @default.
• W4313475839 creator A5016759484 @default.
• W4313475839 creator A5057141052 @default.
• W4313475839 creator A5057451567 @default.
• W4313475839 creator A5064711465 @default.
• W4313475839 creator A5065617339 @default.
• W4313475839 creator A5069693748 @default.
• W4313475839 creator A5077604881 @default.
• W4313475839 creator A5078868305 @default.
• W4313475839 creator A5081327953 @default.
• W4313475839 creator A5084713092 @default.
• W4313475839 creator A5085646989 @default.
• W4313475839 creator A5089840020 @default.
• W4313475839 creator A5089972173 @default.
• W4313475839 date "2023-01-02" @default.
• W4313475839 modified "2023-10-16" @default.
• W4313475839 title "Study of microencapsulated fatty acid antimicrobial activity in vitro and its prevention ability of Clostridium perfringens induced necrotic enteritis in broiler chicken" @default.
• W4313475839 cites W1990619325 @default.
• W4313475839 cites W2045142223 @default.
• W4313475839 cites W2081157135 @default.
• W4313475839 cites W2108833494 @default.
• W4313475839 cites W2156962447 @default.
• W4313475839 cites W2165040417 @default.
• W4313475839 cites W2186884155 @default.
• W4313475839 cites W2313739141 @default.
• W4313475839 cites W2885835166 @default.
• W4313475839 cites W2978552317 @default.
• W4313475839 cites W2997583061 @default.
• W4313475839 cites W3016341927 @default.
• W4313475839 cites W3186279867 @default.
• W4313475839 cites W3202637977 @default.
• W4313475839 cites W3211596172 @default.
• W4313475839 cites W3211742532 @default.
• W4313475839 cites W4205822697 @default.
• W4313475839 doi "https://doi.org/10.1186/s13099-022-00526-9" @default.
• W4313475839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36593526" @default.
• W4313475839 hasPublicationYear "2023" @default.
• W4313475839 type Work @default.
• W4313475839 citedByCount "3" @default.
• W4313475839 countsByYear W43134758392023 @default.
• W4313475839 crossrefType "journal-article" @default.
• W4313475839 hasAuthorship W4313475839A5002093049 @default.
• W4313475839 hasAuthorship W4313475839A5003014253 @default.
• W4313475839 hasAuthorship W4313475839A5012855703 @default.
• W4313475839 hasAuthorship W4313475839A5016759484 @default.
• W4313475839 hasAuthorship W4313475839A5057141052 @default.
• W4313475839 hasAuthorship W4313475839A5057451567 @default.
• W4313475839 hasAuthorship W4313475839A5064711465 @default.
• W4313475839 hasAuthorship W4313475839A5065617339 @default.
• W4313475839 hasAuthorship W4313475839A5069693748 @default.
• W4313475839 hasAuthorship W4313475839A5077604881 @default.
• W4313475839 hasAuthorship W4313475839A5078868305 @default.
• W4313475839 hasAuthorship W4313475839A5081327953 @default.
• W4313475839 hasAuthorship W4313475839A5084713092 @default.
• W4313475839 hasAuthorship W4313475839A5085646989 @default.
• W4313475839 hasAuthorship W4313475839A5089840020 @default.
• W4313475839 hasAuthorship W4313475839A5089972173 @default.
• W4313475839 hasBestOaLocation W43134758391 @default.
• W4313475839 hasConcept C176947019 @default.
• W4313475839 hasConcept C185592680 @default.
• W4313475839 hasConcept C26381139 @default.
• W4313475839 hasConcept C2779116991 @default.
• W4313475839 hasConcept C2780289900 @default.
• W4313475839 hasConcept C2781003072 @default.
• W4313475839 hasConcept C31903555 @default.
• W4313475839 hasConcept C4937899 @default.
• W4313475839 hasConcept C501593827 @default.
• W4313475839 hasConcept C523546767 @default.
• W4313475839 hasConcept C543025807 @default.
• W4313475839 hasConcept C54355233 @default.
• W4313475839 hasConcept C55493867 @default.
• W4313475839 hasConcept C86803240 @default.
• W4313475839 hasConcept C89423630 @default.
• W4313475839 hasConceptScore W4313475839C176947019 @default.
• W4313475839 hasConceptScore W4313475839C185592680 @default.
• W4313475839 hasConceptScore W4313475839C26381139 @default.
• W4313475839 hasConceptScore W4313475839C2779116991 @default.
• W4313475839 hasConceptScore W4313475839C2780289900 @default.
• W4313475839 hasConceptScore W4313475839C2781003072 @default.
• W4313475839 hasConceptScore W4313475839C31903555 @default.
• W4313475839 hasConceptScore W4313475839C4937899 @default.
• W4313475839 hasConceptScore W4313475839C501593827 @default.
• W4313475839 hasConceptScore W4313475839C523546767 @default.
• W4313475839 hasConceptScore W4313475839C543025807 @default.
• W4313475839 hasConceptScore W4313475839C54355233 @default.
• W4313475839 hasConceptScore W4313475839C55493867 @default.
• W4313475839 hasConceptScore W4313475839C86803240 @default.
• W4313475839 hasConceptScore W4313475839C89423630 @default.
• W4313475839 hasIssue "1" @default.
• W4313475839 hasLocation W43134758391 @default.
• W4313475839 hasLocation W43134758392 @default.
• W4313475839 hasLocation W43134758393 @default.
• W4313475839 hasOpenAccess W4313475839 @default.
• W4313475839 hasPrimaryLocation W43134758391 @default.
• W4313475839 hasRelatedWork W2003208180 @default.
• W4313475839 hasRelatedWork W2076387592 @default.

• next